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Abstract
Background: Sarcopenia is defined as the age-related loss of muscle mass, strength, and physical performance. The
original European Working Group on Sarcopenia in Older Persons (EWGSOP1) definition, and its revision (EWGSOP2),
provide new cut-points and alternate measures for sarcopenia diagnosis. However, sarcopenia is rarely diagnosed in
clinical settings owing to its labor-intensive diagnostic process. Given the Short Physical Performance Battery (SPPB)
is a quick, easily administrable, and objective measure of muscle strength and physical performance, both of which
are key components of sarcopenia, this study examined the diagnostic value of the SPPB for this muscle disease.
Methods: A cross-sectional analysis of 294 community-dwelling older persons (≥65 years) was conducted.
Appendicular lean body mass [(ALM) divided by height squared (ALM/h2)], muscle strength (handgrip/sit to stand),
and physical performance [gait speed, timed up and go (TUG) and SPPB] were assessed using validated procedures,
while participants were diagnosed with sarcopenia following the EWGSOP1 and EWGSOP2 criteria. Diagnostic ability
of the SPPB independently and combined with ALM/h2 for sarcopenia was determined using area under the curve
(AUC). Potential cut-points were identified, and sensitivity and specificity calculated.
Results: Prevalence of sarcopenia ranged from 4 to 16% depending on the definition. The SPPB demonstrated
moderate (AUC = 0.644–0.770) value in diagnosing sarcopenia, and a cut-point of ≤8points in SPPB performance
resulted in high sensitivity (82–100%) but low specificity (36–41%) for diagnosing those with severe sarcopenia.
Conclusions: The SPPB displayed acceptable value in diagnosing older adults with severe sarcopenia. Moreover,
the high sensitivity of the SPPB when using the cut-point of ≤8 suggests it may be a favorable screening tool for
sarcopenia in clinical settings where ALM measurements are not available.
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Background
Sarcopenia, the progressive loss of muscle mass, strength
and function, associates with falls, fractures, disability
and mortality [1]. As a result of these adverse outcomes,
sarcopenia was added to the International Classification
of Diseases (ICD-10), allowing for its diagnosis and man-
agement in clinical practice [2]. Currently, several defini-
tions exist for the diagnosis of sarcopenia, with each
presenting their own diagnostic criteria. These include
the European Working Group on Sarcopenia in Older
People (EWGSOP1 and 2), [3, 4] Sarcopenia Definition
and Outcomes Consortium (SDOC), [5] International
Working Group on Sarcopenia (IWGS) [6] and the
population specific Asian Working Group on Sarcopenia
(AWGS) [7]. In regards to the EWGSOP definition, its
most recent update (EWGSOP2) [4] proposed new cut-
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points and a screening process beginning with the use of
the SARC-F [8] for case finding. With these new cut-
points and alternate assessments, wide variations in preva-
lence from 5 to 26% have been reported, [9] which hinders
the diagnosis and management of older adults at risk.
Diagnosing sarcopenia involves assessment of muscle
mass, strength, and/or physical performance. In the EWG-
SOP definitions, dual x-ray absorptiometry (DXA) is rec-
ommended for the assessment of appendicular lean mass
(ALM), corrected for height squared (h2). Meanwhile,
handgrip strength and gait speed are favored for assessment
of muscle strength and physical performance, respectively.
However, substitute measures are also proposed including
the sit to stand test (alternate for handgrip strength), the
timed up and go (TUG) test, and the Short Physical Per-
formance Battery (SPPB) as alternatives for gait speed.
Of these measures, the SPPB assesses muscle strength,
balance and mobility via five timed components, all of
which are quick, easy to administer, and don’t require any
specialized equipment [10]. As such, we sought to exam-
ine the diagnostic value of the SPPB for sarcopenia. This
was carried out by first identifying the prevalence of sarco-
penia using EWGSOP1 and EWGSOP2 definitions. Upon
doing so, the diagnostic value of the SPPB in characteriz-
ing individuals with sarcopenia will be evaluated. Finally,
cut-points for sarcopenia using the SPPB score will be
identified and compared to those currently recommended.
Methods
This was a cross-sectional study of 294 community-
dwelling older adults based in Melbourne, Australia. Par-
ticipants attending the falls and fractures clinic for clinical
assessment between 2016 and 19 were included. Partici-
pants fulfilled the following criteria: aged over 65 years
with a history of falls or at risk of falls, ability to mobilize
independently with or without the use of gait aids, and no
history of cognitive impairment. This study was approved
by the Western Health local Human Ethics Research
Committee (DB2017.13 and QA2018.80–46,205).
Assessments
Participants undertook a comprehensive assessment
which included the identification of risk for falls and
fractures. Falls (in the past year) and fracture (in the past
5 years) history were determined by interview. Assess-
ments of physical performance and balance, as well as
body composition to determine ALM/h2 using DXA
(Hologic Inc., Bedford, MA, USA) were also performed.
Participant reported fear of falling was determined using
the Falls Efficacy Scale – International [11].
Physical performance measures conducted on partici-
pants included the assessment of height and weight for
calculation of body mass index (BMI), handgrip strength,
gait speed, TUG, and SPPB. Handgrip strength was
assessed using a Jamar hydraulic dynamometer (Sammons
Preston Inc.) with the participant seated with their arm
resting on chair arms. Participants were instructed to
squeeze the dynamometer at their maximal effort, with
the test performed 3 times on each side and 30 s rest pro-
vided between each trial. The best score out of the 3 trials
was recorded.
To assess gait speed, we used the GAIT Rite® (CIR Sys-
tems Inc., Havertown, PA) instrumented walkway system
(580 cm × 89 cm × 0.625 cm, sample rate = 120 Hz). The
GAIT Rite mat was used to record spatiotemporal data.
It was positioned along a straight section of the walkway
and participants were instructed to walk at their normal
speed. Three trials were provided with the best gait
speed recorded. Gait aids were used a necessary.
To assess TUG performance, we used a 3-m course
[12]. Participants began in a seated position and were
instructed to stand, walk 3 m to a marked area, then re-
turn to the starting seated position. The TUG test was
performed twice at the participants normal speed with
the best time of completion recorded. A gait aid was
allowed for use as needed.
The SPPB is an assessment which includes 5 tests for
lower limb function, including balance, strength, and
mobility [10]. Balance assessments were composed of 3
parts which progressed in difficulty (feet together stand,
semi tandem and full tandem stand). The aim of the bal-
ance tests was to stand for 10 s unaided, with the test
progressing in difficulty after successful completion. Gait
speed was assessed as previously described (using GAIT
Rite assessment results). The 5 times sit to stand test
was performed with the participant starting in the seated
position. After confirming ability to perform 1 sit to
stand action, participants were then instructed to stand
and sit 5 times as quickly as possible, ensuring feet were
flat on the floor. Scores were allocated according to per-
formance, with an overall maximum score of 12.
Classifying sarcopenia
Sarcopenia status was classified based on the EWGSOP1
and EWGSOP2 definitions. This study focused on those
who were classified as having severe sarcopenia and
therefore fulfilled the 3 criteria for muscle strength,
ALM/h2 and physical performance. Participants were
classified as severely sarcopenic according to 7 different
sarcopenia criteria. Using the EWGSOP1 definition, se-
vere sarcopenia was defined as those with low ALM/h2,
gait speed and handgrip strength. For the EWGSOP2
definition, 6 severe sarcopenia groups were created
based on fulfillment of cut-points for muscle strength
(handgrip strength or sit to stand test), ALM/h2 and
physical performance (low gait speed, SPPB score or in-
creased TUG time).
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Statistical analysis
Baseline characteristics for participants are presented as
a median (IQR) or frequency (%). The diagnostic value
of the SPPB was assessed by calculating the area under
the receiver operating characteristic (ROC) curve separ-
ately for each sarcopenia definition. This was repeated
with the addition of ALM/h2 to the model. Area under
the ROC curve (AUC) of 0.7–0.8 was considered to be
acceptable, with 0.8–0.9 excellent and > 0.9 outstanding
[13]. Optimal cut-points for the SPPB in diagnosing sar-
copenia were defined by 3 different methods: maximiz-
ing the product of sensitivity and specificity (Liu), [14]
maximizing their sum (Youden) [15] and cut-point on
the ROC curve closest to perfect sensitivity and specifi-
city (Nearest 0,1) [16]. All analyses were performed
using Stata 15.1 (StataCorp. 2017. Stata Statistical Soft-
ware: Release 15. College Station, TX: StataCorp LLC).
Results
Baseline characteristics
A total of 294 participants (77.2% women) with a median
age of 78 years (IQR 73, 83) were included in this analysis
(Table 1). Sarcopenia prevalence ranged from 4 to 16% de-
pending on the criteria employed (Table 2). EWGSOP1
and 2 definitions based on handgrip strength, ALM/h2
and gait speed showed similar prevalence of sarcopenia at
12 and 8%, respectively. Highest prevalence of sarcopenia
was evident when using the sit to stand, ALM/h2 and
SPPB or gait speed criteria at 16%, with the lowest preva-
lence observed when diagnosing sarcopenia by handgrip
strength, ALM/h2 and TUG (4%). Number of falls, per-
formance in SPPB and gait speed were similar between all
sarcopenia categories except those diagnosed using TUG
for physical performance. Handgrip strength varied
between groups with those using the sit to stand test to
diagnose low muscle strength exhibiting the highest hand-
grip strength. Prevalence for each sarcopenia group and
baseline characteristics of participants in each sarcopenia
category can be found in Table 2.
Diagnostic value of SPPB
Use of the SPPB resulted in moderate diagnostic value
for sarcopenia for all EWGSOP definitions with AUC
ranging from 0.644 to 0.770, as shown in Table 3. The
lowest AUC occurred when using the SPPB to diagnose
sarcopenia by the recommended EWGSOP2 criteria of
low handgrip strength, ALM/h2 and gait speed (AUC =
0.644). Highest AUC for use of the SPPB was found
when diagnosing EWGSOP2 sarcopenia according to the
alternate measures of sit to stand, ALM/h2 and TUG
(AUC = 0.770).
Diagnostic value of SPPB combined with ALM/h2
When combining the SPPB with ALM/h2, there was a sig-
nificant increase in the diagnostic capability. AUC for both
the EWGSOP1 and 2 was increased, with AUC in an ‘ex-
cellent’ range for all groups, between 0.846 and 0.897. The
lowest AUC was evident using the EWGSOP1 criteria for
severe sarcopenia (AUC= 0.846), with AUC observed in
the EWGSOP2 criteria of sit to stand, ALM/h2 and TUG
performance (AUC= 0.897). An overview of the AUC for
use of the SPPB combined with ALM/h2 in diagnosing
each severe sarcopenia group can be found in Table 3.
Potential SPPB cut-points for diagnosing sarcopenia
Optimal cut-points for use of the SPPB alone to diagnose
sarcopenia varied depending on method and ranged from
4 to 8 points. All cut-points resulted in either high sensi-
tivity and low specificity or vice versa (Table 4). The cur-
rently recommended cut-point of ≤8 produced high
sensitivity (82–100%) but low specificity (36–41%) for all
sarcopenia definitions. Most commonly observed optimal
cut-points in SPPB performance were 5 and 6, which re-
sulted in sensitivity and specificity between 60 and 75%.
Discussion
We examined the diagnostic value of the SPPB alone
and in combination with ALM/h2 in diagnosing sarcope-
nia in community-dwelling older adults. We character-
ized the sensitivity and specificity of currently
recommended cut-points, in addition to new cut-points
based on our study population, and found two main
findings. Firstly, the SPPB alone resulted in moderate
diagnostic value but increased to an excellent level when
combined with DXA measured ALM/h2. This was re-
gardless of which definition (EWGSOP1 or EWGSOP2)
was employed. Secondly, the currently recommended
SPPB cut-point of ≤8 showed high sensitivity for
Table 1 Baseline characteristics of participants (n = 294)
Median (IQR)
Age (yrs) 78.2 (73, 83)
Sex (women), n (%) 227 (77.2%)
Weight (kg) 70 (59, 80.8)
Height (cm) 157 (152, 164)
Body Mass Index (kg/m2) 28.04 (23.92, 31.45)
ALM/h2 6.33 (5.72, 7.22)
Falls in past year 2 (1, 3)
Fractures 1 (1, 1)
Handgrip strength (kg) 21 (16, 28)
SPPB total score 7 (5, 9)
Timed Up and Go (s) 16.14 (11.63, 21.50)
Gait Speed (m/s) 0.70 (0.53, 0.92)
FES-I 34 (24, 45)
ALM/h2 Appendicular Lean Mass corrected for height squared, SPPB Short
Physical Performance Battery, FES-I Falls Efficacy Scale – International
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sarcopenia, however, a more conservative cut-point of
≤6 provided the greatest specificity. It therefore appears
that the SPPB represents an objective screening tool to
diagnose those at risk of sarcopenia.
The SPPB has been used to monitor physical perform-
ance in both healthy community-dwelling older adults as
well as hospitalized patients [17–20]. This measure is ad-
vantageous in that minimal equipment is required to per-
form the test, and objective data is provided on muscle
strength, gait speed and standing balance. In addition, spe-
cific components of the SPPB can independently predict
the risk of declines in activities of daily living, [21] falls,
[22] hospitalization [23] and mortality [23]. Furthermore,
the SPPB can be used as a sensitive monitoring tool for
lower limb physical performance with a change of 1 point
considered clinical significant [24]. These factors place the
SPPB as an ideal tool for the diagnosis of sarcopenia in
clinical settings and subsequent monitoring of resistance
exercise (RE) interventions which are, at present, the most
efficacious treatment for this muscle disease [25]. While
other tools such as handgrip strength are reliable, easy to
administer and a good marker of whole-body strength,
they are poor responders to RE interventions [26]. Thus,
the strength component of the SPPB should be assessed
by sit to stand time, which is a reliable marker of lower
limb strength and is sensitive to change [4].
Our findings show the SPPB displayed acceptable diag-
nostic value for sarcopenia. When employing the most
common cut-points of ≤6, sensitivity and specificity was
65 and 63%, respectively. This cut-point has been associ-
ated with more than 3-fold likelihood of recurrent falls for
both men and women, [27] one of the primary adverse
outcomes of sarcopenia. Indeed, those diagnosed as sarco-
penic (using the EWGSOP1) reported a 3-fold increased
risk of falls compared to non-sarcopenic adults [28].
When increasing this cut-point to ≤8, the sensitivity and
specificity increased to 100 and 41%, respectively. In line
with this, this is the cut-point recommended for poor
physical performance by the EWGSOP criteria. Despite
the excellent sensitivity, the poor specificity of this cut-
point indicates that the SPPB cannot be solely used for the
diagnosis of sarcopenia.
Table 2 Characteristics of participants according to sarcopenia groups
EWGSOP1 EWGSOP2
ALM/h2 + HG +
GS
HG + ALM/h2 +
GS
HG + ALM/h2 +
TUG
HG + ALM/h2 +
SPPB
STS + ALM/
h2 + GS
STS + ALM/h2 +
TUG
STS + ALM/h2 +
SPPB
Prevalence 36 (12%) 22 (8%) 12 (4%) 19 (7%) 46 (16%) 24 (8%) 47 (16%)
Age (yrs) 81.5 (76, 84) 82.5 (76, 84) 83 (78.5, 84.5) 82 (76, 85) 80 (75, 84) 80.5 (76, 84) 81 (76, 85)
Sex (women), n
(%)
22 (61%) 14 (64%) 7 (58%) 12 (63%) 32 (70%) 16 (67%) 32 (68%)
Weight (kg) 57.3 (50.6, 67.6) 55.3 (50, 66) 56.7 (50.1, 65.7) 55.2 (50, 66) 57.6 (51, 64.1) 56.3 (50.2, 63.5) 56 (50, 64)
Height (cm) 155 (151, 163) 154 (149, 163) 156 (151, 163) 155 (152, 163) 156 (151, 163) 157 (150, 165) 157 (152, 163)
Body Mass Index 23.79 (21.83,
26.19)
23.41 (20.81,
26.01)
23.39 (21.44,
25.61)
22.97 (20.28,
25.20)
23.26 (21.17,
26.01)
22.49 (21.45,
24.64)
23.23 (20.81,
25.20)
ALM/h2 5.42 (5.12, 5.92) 5.40 (5.12, 5.67) 5.38 (5.04, 5.58) 5.26 (5.04, 5.67) 5.22 (5.00, 5.67) 5.23 (5.02, 5.58) 5.23 (5.03, 5.83)
Falls in past year 2 (1, 2) 2 (1, 2) 2 (1, 3.5) 2 (1, 3) 2 (1, 2) 2 (1, 2.5) 2 (1, 3)
Handgrip strength
(kg)
16 (12, 20) 13.5 (11, 17) 13.5 (12, 19) 12 (11, 18) 20 (15, 24) 19.5 (15, 22) 20 (14, 24)
SPPB score 5.5 (4.5, 7.0) 6 (4, 8) 4 (2.5, 6.5) 5 (4, 7) 5.5 (4, 7) 4.5 (4, 6) 6 (4, 7)
Timed Up and Go
(s)
19.31 (16.71,
24.39)
19.50 (16.71,
24.39)
25.09 (22.27,
33.94)
19.77 (16.81,
25.80)
19.46 (16.71,
24.39)
25.09 (21.62,
29.92)
19.23 (15.42,
24.39)
Gait Speed (m/s) 0.54 (0.39, 0.69) 0.51 (0.38, 0.66) 0.38 (0.26, 0.61) 0.50 (0.38, 0.65) 0.56 (0.40, 0.70) 0.46 (0.33, 0.62) 0.56 (0.40, 0.71)
FES-I 36 (25.5, 48.5) 36.5 (29, 52) 50 (29, 59.5) 38 (29, 57) 37 (26, 48) 43.5 (26.5, 52.5) 36 (25, 48)
ALM/h2 Appendicular Lean Mass corrected for height squared, GS Gait speed, HG Handgrip strength, SPPB Short Physical Performance Battery, TUG Timed up and
go, FES-I Falls Efficacy Scale – International
Table 3 Area under curve (AUC) for use of Short Physical
Performance Battery (SPPB) alone, or in combination with
Appendicular Lean Mass corrected for height (ALM/h2)
Definition Criteria AUC
SPPB
AUC
SPPB + ALM/h2
EWGSOP1 ALM/h2 + GS + HG 0.678 0.846
EWGSOP2 HG + ALM/h2 + GS 0.644 0.849
HG + ALM/h2 + TUG 0.767 0.870
HG + ALM/h2 + SPPB 0.715 0.873
STS + ALM/h2 + GS 0.701 0.893
STS + ALM/h2 + TUG 0.770 0.897
STS + ALM/h2 + SPPB 0.703 0.889
GS Gait speed, HG Handgrip strength, SPPB Short Physical Performance Battery,
TUG Timed up and go
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Highly sensitive tests have been proposed as ideal tools
for screening purposes, allowing for the early identifica-
tion and initiation of treatment [29]. Meanwhile, high
specificity has been reported as the key diagnostic factor
for a disease, with a combination of high sensitivity/low
specificity and low sensitivity/high specificity test an
ideal method to address false positives [29]. Using this
model, the SPPB displays high sensitivity and represents
the ideal screening tool for sarcopenia. Alternately, the
SARC-F tool has consistently shown high specificity in
numerous studies [30, 31] and may therefore facilitate
the diagnostic process. This combined approach repre-
sents an area for further research given the potential to
enhance clinical care.
Sarcopenia in its current form includes the assessment
of muscle strength, mass, and physical performance.
However, whilst measures of strength and physical per-
formance have shown links to adverse outcomes of sar-
copenia, the same relationship is not observed with
ALM [32, 33]. Our findings corroborate previous studies
which have shown the disconnect between measures of
muscle strength and physical performance and muscle
mass. This is represented by the poor to acceptable
AUC when using the SPPB as an independent diagnostic
tool. However, a combination of SPPB with ALM/h2
resulted in increased AUC, matching well with both ini-
tial and revised EWGSOP sarcopenia criteria, with the
highest diagnostic value evident using the sit to stand
test combined with ALM/h2 and either gait speed or
SPPB. This was somewhat expected given both the sit to
stand test and gait speed are already components of the
SPPB. However, it was surprising to observe that the
combination of SPPB and ALM/h2 yielded an increased
AUC for all the other diagnostic criteria proposed by
EWGSOP2. Given the SPPB is a tool which can be easily
implemented into the routine care of patients without a
need for specialized equipment, this finding may provide
useful in clinical practice.
In the current study, we diagnosed participants present-
ing with severe sarcopenia which is a strength given that
our previous findings showed that the severity of sarcope-
nia was the driving factor that increased falls and fractures
[34]. Studies assessing the impact of sarcopenia in modu-
lating balance performance are required to further efforts
in developing interventions. The findings of the present
study should also be taken in context of the limitations.
Firstly, our population, although community-dwelling, re-
ported a history of falls and/or fractures. Therefore, results
may have been biased given that these participants are at
increased risk for sarcopenia. Secondly, the cross-sectional
Table 4 Sensitivity and specificity for cut-points for sarcopenia based on definition
Definition Criteria Method Cut-point (≤) Sensitivity (95% CI) Specificity (95% CI)
EWGSOP1 ALM/h2 + GS + HG Liu, Youden 7 81% (64, 92) 48% (41, 54)
Nearest (0,1) 6 61% (44, 77) 62% (55, 68)
Current literature 8 89% (74, 97) 38% (32, 44)
EWGSOP2 HG + ALM/h2 + GS Liu, Youden 5 46% (24, 68) 74% (68, 79)
Nearest (0,1) 6 55% (32, 76) 60% (54, 66)
Current literature 8 82% (60, 95) 36% (30, 42)
HG + ALM/h2 + TUG Liu, Nearest (0,1) 5 67% (35, 90) 74% (68, 79)
Youden 4 58% (28, 85) 84% (79, 88)
Current literature 8 92% (62, 100) 36% (30, 41)
HG + ALM/h2 + SPPB Liu, 7 84% (60, 97) 46% (40, 52)
Youden 8 100% (82, 100) 37% (31, 43)
Nearest (0,1) 6 63% (38, 84) 60% (54, 66)
Current literature 8 100% (82, 100) 37% (31, 43)
STS + ALM/h2 + GS Liu, Nearest (0,1) 6 65% (50, 79) 63% (57, 69)
Youden 8 94% (82, 99) 40% (33, 46)
Current literature 8 94% (82, 99) 40% (33, 46)
STS + ALM/h2 + TUG All 5 67% (45, 84) 76% (70, 81)
Current literature 8 96% (79, 100) 37% (31, 43)
STS + ALM/h2 + SPPB Liu, Youden 8 100% (93, 100) 41% (35, 47)
Nearest (0,1) 6 64% (49, 77) 63% (57, 69)
Current literature 8 100% (93, 100) 41% (35, 47)
ALM/h2 Appendicular Lean Mass corrected for height, GS Gait speed, HG Handgrip strength, SPPB Short Physical Performance Battery, TUG Timed up and go
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nature of our study limits our findings as we are unable to
determine whether longitudinally the participants classi-
fied as sarcopenic experienced adverse outcomes such as
falls. Employing a longitudinal study design would have
strengthened the findings.
Conclusion
This study provides an insight into the use of the SPPB
for diagnosing sarcopenia according to the initial and re-
vised EWGSOP definitions. Despite the acceptable diag-
nostic value, no cut-points could be determined which
provided high sensitivity and specificity. However, a cut-
point of ≤8 in the SPPB showed high sensitivity. There-
fore, the SPPB may be used as a screening tool for sarco-
penia to trigger further investigations and early
intervention. The combination of the highly sensitive
SPPB with a highly specific test may prove to be of great
use to clinicians for diagnosing and treating sarcopenia,
however, requires further investigation in longitudinal
trials.
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